Last update Sept. 21, 2023

Atazanavir Sulfate (ATV)

Likely Compatibility

Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.

HIV protease inhibitor antiviral. Used alone or potentiated with Cobicistat or Ritonavir and associated with other antivirals to avoid the development of resistance in the treatment of HIV/AIDS. Oral administration in a daily dose.

It is excreted in breast milk in clinically insignificant amounts. (Spencer 2009)

It is used in infants from 3 months of age. (Kiser 2011)

"Individuals with HIV who are on ART with a sustained undetectable viral load and who choose to breastfeed should be supported in this decision". (Panel 2022 p ix)


See below the information of these related products:

  • Cobicistat (Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.)
  • Maternal HIV-AIDS. Maternal HIV infection (Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.)

Alternatives

We do not have alternatives for Atazanavir Sulfate (ATV).

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

Atazanavir Sulfate (ATV) in other languages or writings:

Group

Atazanavir Sulfate (ATV) belongs to this group or family:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 60 - 68 %
Molecular weight 803 daltons
Protein Binding 86 %
pKa 11.92 -
Tmax 2 - 3 hours
T½ 7 - 8.6 hours
M/P ratio 0.07 - 0.09 -
Theoretical Dose 0.03 - 0.06 mg/Kg/d
Relative Dose 0.6 - 1.26 %

References

  1. Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission. Recommendations for the Use of Antiretroviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States. Department of Health and Human Services. 2023 Consulted on June 16, 2023 Abstract Full text (link to original source)
  2. Kiser JJ, Rutstein RM, Samson P, Graham B, Aldrovandi G, Mofenson LM, Smith E, Schnittman S, Fenton T, Brundage RC, Fletcher CV. Atazanavir and atazanavir/ritonavir pharmacokinetics in HIV-infected infants, children, and adolescents. AIDS. 2011 Jul 31;25(12):1489-96. Abstract Full text (link to original source)
  3. Spencer L, Neely M, Mordwinkin N, et al. Intensive PK of zidovudine (AZT), lamivudine (3TC), and atazanavir (ATV) and HIV-1 viral load in breast milk and plasma in HIV+ women receiving HAART therapy. Presented at: 16th Conference on Retroviruses and Opportunistic Infections; Montreal, Canada. 8–11 February 2009. Abstract 942. 2009

Total visits

775

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM